Skip to main content

Table 1 Demographic and clinical variables, mean (standard deviation)

From: EEG alpha reactivity and cholinergic system integrity in Lewy body dementia and Alzheimer’s disease

 

HC (N = 40)

AD (N = 21)

LBD (N = 41)

Group differences

Male to female

25:15

14:7

35:6

χ2 = 5.8, p = 0.06a

Age

73.4 (6.6)

74.7 (7.2)

74.6 (6.5)

F(2, 99) = 0.4, p = 0.66b

AChEI

20

35

χ2 = 1.4, p = 0.25c

PD meds

0

28

χ2 = 26.2, p < 0.001c

Duration

4.1 (2.4)f

3.2 (2.1)g

U = 270, p = 0.07d

MMSE

28.8 (1.1)

21.6 (3.7)

23.1 (3.8)

t60 = 1.5, p = 0.15e

UPDRS III

3.9 (4.2)

1.7 (1.5)

20.2 (8.6)

t60 = 9.7, p < 0.001e

CAF total

0.3 (0.7)h

5.2 (4.3)j

t56 = 5.1, p < 0.001e

Mayo total

9.4 (4.4)h

14.3 (5.5)j

t56 = 3.5, p = 0.001e

Mayo cogn

2.0 (1.9)h

3.0 (1.8)j

t56 = 2.0, p = 0.05e

NPI total

7.4 (7.2)h

14.5 (10.5)g

t58 = 2.7, p = 0.009e

NPI hall

0.05 (0.2)h

2.0 (2.0)g

t58 = 4.5, p < 0.001e

  1. AChEI number of patients taking acetylcholinesterase inhibitors, AD Alzheimer’s disease, CAF total Clinician Assessment of Fluctuation total score, Duration duration of cognitive symptoms in years, HC healthy controls, LBD Lewy body dementia, Mayo total Mayo Fluctuation Scale, Mayo cognitive Mayo Fluctuation cognitive subscale, MMSE Mini-Mental State Examination, PD meds number of patients taking dopaminergic medication for the management of Parkinson’s disease symptoms, UPDRS III Unified Parkinson’s Disease Rating Scale III (motor subsection), NPI Neuropsychiatric Inventory, NPI hall NPI hallucination subscore
  2. aChi-square test HC, AD, LBD
  3. bOne-way ANOVA HC, AD, LBD
  4. cChi-square test AD, LBD
  5. dMann-Whitney U test AD, LBD
  6. eStudent’s t test AD, LBD
  7. fN = 19
  8. gN = 40
  9. hN = 20
  10. jN = 38